OncLive SOSS

Authors

Latest:

Unraveling the Layers: IDNs, ACOs, and the Future of Healthcare Integration

This recorded webinar features thought leader perspectives and key insights from HRA's newest research program - Understanding Integrated Delivery Networks.

Hristos Kaimakliotis, MD

Latest:

Dr. Hristos Kaimakliotis on Predictive Markers in Bladder Cancer

Hsingwen Chung, BS Pharm, MS

Latest:

Treatment Patterns of Metastatic Triple-Negative Breast Cancer in US Community Practice Settings

First-line treatment patterns for metastatic triple-negative breast cancer are diverse, reflecting a lack of consensus and an unmet need for standardized therapy.

Latest:

Dr. Ford on Docetaxel in Esophagogastric Cancer

Hugo Ford, MD, from the Addenbrooke's Hospital in Cambridge, UK, describes which patients with metastatic esophagogastric cancer derive the greatest benefit from second-line treatment with docetaxel.

Hugues Bourgeois, MD

Latest:

SABCS Interview Series

The January issue of OBTN featured highlights from the 32nd Annual San Antonio Breast Cancer Symposium (SABCS). We wrap up our SABCS coverage this month with interviews on denosumab with Alison Stopeck, MD, associate professor of medicine at the University of Arizona and director of the Clinical Breast Cancer Program at the Arizona Cancer Center; oral bisphosphonates with Rowan T.Chlebowski, MD, PhD, professor and chief of the Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center; and adjuvant chemotherapyÃƒÂ¢Ã¯Â¿Â½Ã¯Â¿Â½induced alopecia with Hugues Bourgeois, MD, Centre Jean Bernard in Lemans, France.

Hui-Kuo Shu, MD, PhD

Latest:

Advanced 3D MRI Technology Marks a Leap Forward in Glioblastoma Imaging

Although advances have been made in imaging techniques for patients with glioblastoma multiforme, new tools are needed to supplement standard imaging sequences.

Hui-Zi Chen, MD, PhD

Latest:

Dr. Chen on Rapid Research Autopsy in Rare Cancer

Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.

Huma Q. Rana, MD

Latest:

Dr. Rana on the Rationale for Video Genetic Counseling in Prostate Cancer

Huma Q. Rana, MD, MPH, discusses the rationale for the ProGen trial, which compared the effectiveness of video education versus in-person genetic counseling for men with prostate cancer.

Humberto Choi, MD

Latest:

Dr. Choi on Using Low-Dose CT Scans to Screen for Lung Cancer

Humberto Choi, MD, discusses using low-dose CT scans to screen patients with a high-risk of developing lung cancer.

Latest:

Dr. Lee on Potential Challenges With VLS-101 in MCL and DLBCL

Hun Ju Lee, MD, discusses potential challenges with VLS-101 in mantle cell lymphoma and diffuse large B-cell lymphoma.

Hung T. Khong, MD

Latest:

Dr. Khong on the Importance of BRCA Testing in Breast Cancer

Hung Khong, MD, underscores the importance of testing for BRCA mutations in patients with breast cancer.

Hussein A. Tawbi, MD, PhD

Latest:

Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years

A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.

Hussein A. Tawbi, MD, PhD, University of Texas MD Anderson Cancer Center

Hussein A. Tawbi, MD, University of Texas MD Anderson Cancer Center

Hussein Aoun, MD

Latest:

Dr. Aoun on Imaging Modalities in Prostate Cancer

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.

Hussein Tawbi, MD, PhD, UT MD Anderson Cancer Center

Hye Sook Chon, MD

Latest:

Dr Chon on Durvalumab Plus Chemotherapy and Olaparib in Endometrial Cancer

Hye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.

Hyman B. Muss, MD

Latest:

Dr. Muss on the Use of Metronomic Chemotherapy in Metastatic Breast Cancer

Hyman B. Muss, MD, discusses the use of metronomic chemotherapy in metastatic breast cancer.

Hyun C. Chung, MD, PhD

Latest:

Dr. Chung on the Rationale of the KEYNOTE-811 Trial in HER2+ Gastric Cancer

Hyun C. Chung, MD, PhD, discusses the rationale of the KEYNOTE-811 study in HER2-positive gastric cancer.

Hyung L. Kim, MD

Latest:

Dr. Kim on Combining Immunotherapy and TKIs in Metastatic RCC

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the potential combination of immunotherapy and tyrosine kinase inhibitors in metastatic renal cell carcinoma.